TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
HURATAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S Food and Drug Administration's (FDA)...
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
HURATAMPA, Fla., Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for...
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
HURATAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright...
FDA Removes Manufacturing-Related Partial Clinical Hold On TuHURA's Phase 3 Accelerated Approval Trial For IFx-2.0, Allowing Trial To Proceed As Agreed To Under Previously Announced SPA Agreement With FDA
HURATuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster At 2025 ASCO Annual Meeting
HURAHC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $12 Price Target
HURATuHURA Biosciences Q1 EPS $(0.15) Misses $(0.10) Estimate
HURATuHURA Biosciences Initiates Phase 1b/2a Study Of IFx-Hu2.0 As An Adjunctive Therapy To Keytruda In First Line Treatment For Metastatic Merkel Cell Carcinoma Of Unknown Primary Origin
HURATuHURA Biosciences And Kineta Present Updated Results From Kineta's Phase I-II Study Of KVA12123 And TuHURA's Mechanism Of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure In Advanced Melanoma
HURAHC Wainwright & Co. Maintains Buy on TuHURA Biosciences, Lowers Price Target to $12
HURATuHURA Biosciences FY24 EPS ($1.21) Up From ($2.47) YoY
HURAHC Wainwright & Co. Initiates Coverage On TuHURA Biosciences with Buy Rating, Announces Price Target of $13
HURARodman & Renshaw Initiates Coverage On TuHURA Biosciences with Buy Rating, Announces Price Target of $11
HURA